Ube Industries To Expand Pharma Business In China And India
This article was originally published in PharmAsia News
Executive SummaryTokyo-based Ube Industries is expanding its new drug discovery and contract manufacturing business with Chinese and Indian drug makers
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.